非增强CT大梗死核心卒中患者血栓切除术:TESLA随机临床试验
TESLA试验在47个美国中心纳入300例发病24小时内前循环大血管闭塞且非增强CT显示大梗死核心(ASPECTS 2-5分)的患者,随机接受血栓切除术或常规内科治疗。90天UW-mRS评分干预组2.93 vs 对照组2.27,调整差值0.63(95%CrI -0.09至1.34;优效后验概率0.96),未达预设0.975显著性阈值;90天死亡率两组相似(35.3% vs 33.3%)。
要点
- 非增强CT大梗死核心患者血栓切除术未显著改善90天功能结局
- 90天死亡率干预组35.3% vs 对照组33.3%,两组相似
- 症状性颅内出血干预组4.0% vs 对照组1.3%
核心结论
- 在非增强CT显示大梗死核心且发病24小时内的患者中,血栓切除术未显示功能结局改善。
- 效应估计的可信区间宽度涵盖无重要效应与临床相关获益两种可能,该影像方法和时间窗下血栓切除术的潜在作用可能需要额外研究。
研究设计与样本
- 开放标签、盲法终点、贝叶斯适应性随机试验,设期中分析用于早期停止(无效或成功)或人群富集。
- 在47个美国学术和社区卒中血栓切除中心开展,2019年7月16日至2022年10月17日入组,末次随访2023年1月25日。
- 300例发病24小时内前循环大血管闭塞且非增强CT显示大梗死核心(ASPECTS 2-5分)的患者随机接受血栓切除术或常规医疗。
- 干预组152例接受标准血栓切除装置血管内治疗加常规医疗,对照组148例仅接受常规医疗。
主要发现
- 主要疗效终点90天UW-mRS均值(SD):干预组2.93(3.39) vs 对照组2.27(2.98),调整差值0.63(95%CrI -0.09至1.34;血栓切除优效后验概率0.96)。
- 90天死亡率:干预组35.3%(53/150) vs 对照组33.3%(49/147),两组相似。
- 24小时症状性颅内出血:干预组4.0%(6/151) vs 对照组1.3%(2/149)。
- 脑实质血肿1型:干预组9.5%(14/148) vs 对照组2.7%(4/146);脑实质血肿2型:干预组9.5%(14/148) vs 对照组3.4%(5/146);蛛网膜下腔出血:干预组16.2%(24/148) vs 对照组6.2%(9/146)。
关键数值与推荐
- 主要疗效终点为90天功能结局改善,采用均值效用加权改良Rankin量表(UW-mRS)评分(范围0[死亡或严重残疾]至10[无症状];最小临床重要差异0.3)。
- 贝叶斯模型确定干预优于常规医疗的后验概率,统计学显著性为单侧后验概率≥0.975。
- 主要不良事件终点为90天死亡率;次要不良事件终点包括症状性颅内出血和影像学颅内出血。
临床怎么用
- 原文未据此给出推荐。
局限性
- 效应估计的可信区间宽度涵盖无重要效应与临床相关获益两种可能。
- 该影像方法和时间窗下血栓切除术的潜在作用可能需要额外研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Recent large infarct thrombectomy trials used heterogeneous imaging modalities and time windows for patient selection. Noncontrast computed tomographic (CT) scan is the most common stroke imaging approach. It remains uncertain whether thrombectomy is effective for patients with large infarcts identified using noncontrast CT alone within 24 hours of stroke onset. OBJECTIVE: To evaluate the effect of thrombectomy in patients with a large infarct on a noncontrast CT scan within 24 hours of onset. DESIGN, SETTING, AND PARTICIPANTS: Open-label, blinded-end point, bayesian-adaptive randomized trial with interim analyses for early stopping (futility or success) or population enrichment, which was conducted at 47 US academic and community-based stroke thrombectomy centers. Three hundred patients presenting within 24 hours with anterior-circulation, large-vessel occlusion and large infarct on noncontrast CT scan, with Alberta Stroke Program Early CT Scores of 2 to 5, were randomized to undergo thrombectomy or usual care. Enrollment occurred July 16, 2019 to October 17, 2022; final follow-up, January 25, 2023. INTERVENTION: The intervention patients (n = 152) underwent endovascular treatment using standard thrombectomy devices and usual medical care. Control patients (n = 148) underwent usual medical care alone. MAIN OUTCOMES AND MEASURES: The primary efficacy end point was improvement in 90-day functional outcome measured using mean utility-weighted modified Rankin Scale (UW-mRS) scores (range, 0 [death or severe disability] to 10 [no symptoms]; minimum clinically important difference, 0.3). A bayesian model determined the posterior probability that the intervention would be superior to usual care; statistical significance was a 1-sided posterior probability of .975 or more. The primary adverse event end point was 90-day mortality; secondary adverse event end points included symptomatic intracranial hemorrhage and radiographic intracranial hemorrhage. RESULTS: The trial enrolled 300 patients (152 intervention, 148 control; 138 females [46%]; median age, 67 years), without early stopping or enrichment; 297 patients completed the 90-day follow-up. The mean (SD) 90-day UW-mRS score was 2.93 (3.39) for the intervention group vs 2.27 (2.98) for the control group with an adjusted difference of 0.63 (95% credible interval [CrI], -0.09 to 1.34; posterior probability for superiority of thrombectomy, .96). The 90-day mortality was similar between groups: 35.3% (53 of 150) for the intervention group vs 33.3% (49 of 147) for the control group. Six of 151 patients (4.0%) in the intervention group and 2 of 149 (1.3%) in the control group experienced 24-hour symptomatic intracranial hemorrhage. Fourteen patients of 148 (9.5%) in the intervention group vs 4 of 146 (2.7%) in the control group experienced parenchymal hematoma type 1 hemorrhages; 14 (9.5%) in the intervention group vs 5 (3.4%) in the control group experienced parenchymal hematoma type 2 hemorrhages; and 24 (16.2%) in the intervention group vs 9 (6.2%) in the control group experienced subarachnoid hemorrhages. CONCLUSIONS AND RELEVANCE: Among patients with a large infarct on noncontrast CT within 24 hours, thrombectomy did not demonstrate improvement in functional outcomes. But the width of the credible interval around the effect estimate includes the possibility of both no important effect and a clinically relevant benefit, so the potential role of thrombectomy with this imaging approach and time window will likely require additional study. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03805308.
引用
- Yoo AJ, Zaidat OO, Sheth SA, et al. Thrombectomy for Stroke With Large Infarct on Noncontrast CT: The TESLA Randomized Clinical Trial. JAMA. 2024. PMID: 39374319. doi:10.1001/jama.2024.13933
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。